Business Wire

LACERO

9.6.2020 09:02:08 CEST | Business Wire | Press release

Share
Lacero Launches First Dedicated Governance Platform for Digital Assets With Major Liquidity Provider B2C2

Lacero, a next generation governance technology provider for digital assets, today announced the launch of FlowOS, offering advanced transaction control and permissioning. FlowOS is now live with major cryptocurrency liquidity provider B2C2.

FlowOS enhances existing wallet and custody solutions, giving users direct, independent control of their policies, procedures and rules. A radically different solution, it is the first platform to leverage blockchain technology to create a decentralised, immutable security architecture by constructing policy from independently certified smart contracts.

Introducing real-time governance, traceability and auditability, it makes it impossible to substitute, manipulate or circumvent approved policies and procedures, and enables reliable exception-based processing with a combination of programmable rules, automated workflow procedures and human approvals.

B2C2 has selected Lacero for its best-in-class technology for governance, controls and procedures. B2C2’s integration of FlowOS, in combination with its existing integration of Fireblocks’ cutting-edge payments technology, will further enhance the firm’s settlement capabilities – the largest by some margin in the OTC markets – for the benefit of its clients.

This combination of technology platforms further demonstrates B2C2’s bank-grade security and compliance standards which, twinned with its award-winning technology and the tightest and most consistent pricing, has made it the OTC liquidity provider of choice to the largest institutional names in the industry.

B2C2’s settlement platform, enhanced by the decentralised, auditable solutions offered by Lacero and Fireblocks, is setting a market standard for straight-through-processing that is applicable to both cryptocurrency and traditional financial markets.

Rashid Hoosenally, CEO of Lacero, said: “We’re excited to be partnering with a proven industry leader who shares our vision for institutional-grade governance and controls. B2C2 strive to continuously optimise processes and tailor workflows, so we’re delighted that FlowOS has been selected to provide them with a secure, flexible enforcement platform that can support them as they grow the scale, speed and breadth of their offering.”

Max Boonen, Founder and Group CEO of B2C2, said: “B2C2’s mission to bring best practices to the trading of digital assets spans both execution and post-trade. The ability to streamline and automate both trading and settlement is the next frontier in our industry. Enhancing the B2C2 platform with Lacero’s innovative technology will allow us to better serve our clients and further scale our business as the go-to counterparty.”

Simon Heinrich, CIO and Group Head of Technology at B2C2, said: “Operational excellence and client service are at the heart of what we do at B2C2 as we are relied upon to provide institutional-grade liquidity 24/7. Given the trustless environment and irreversibility of transactions in the continuously traded and settled crypto markets, FlowOS represents a critical component of our offering as it enables controlled autonomy of our processes in a demonstrably secure way.”

-Ends-

About Lacero
Lacero develops innovative technology for governing and safeguarding digital assets and data. Its platform is underpinned by blockchain, certified smart contracts and highly secure cryptographic methods. Based in the UK, Lacero was awarded Best RegTech Policy Platform 2020 in Wealth and Finance International’s FinTech Awards. For more information on Lacero’s FlowOS platform, please visit https://www.lacero.io

About B2C2
Founded in 2015, B2C2 is the leading cryptocurrency liquidity provider. Awarded Cryptocurrency Innovation of the Year in 2020 by FStech and Best Institutional Crypto Liquidity Provider in 2019 by the readers of Profit & Loss, B2C2 bridges the gap between traditional financial and cryptocurrency markets. The company is trusted by brokerages, exchanges, banks and fund managers to provide 24/7 liquidity. Headquartered in the UK, with offices in London, Jersey City and Tokyo, the firm is privately held. For more information, please visit https://www.b2c2.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye